| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8617580 | GALDERMA LABS LP | Compositions for topical application comprising a peroxide and retinoid |
Feb, 2028
(4 years from now) | |
| US9868103 | GALDERMA LABS LP | Metal oxide coating of water insoluble ingredients |
Aug, 2028
(4 years from now) | |
| US10653899 | GALDERMA LABS LP | Core stabilized microcapsules, method of their preparation and uses thereof |
Dec, 2030
(7 years from now) | |
| US11071878 | GALDERMA LABS LP | Core stabilized microcapsules, method of their preparation and uses thereof |
Dec, 2030
(7 years from now) | |
| US10420743 | GALDERMA LABS LP | Methods and compositions for the treatment of acne |
Jul, 2038
(14 years from now) | |
Twyneo is owned by Galderma Labs Lp.
Twyneo contains Benzoyl Peroxide; Tretinoin.
Twyneo has a total of 5 drug patents out of which 0 drug patents have expired.
Twyneo was authorised for market use on 26 July, 2021.
Twyneo is available in cream;topical dosage forms.
Twyneo can be used as topical treatment of acne vulgaris in adults and pediatric patients 9 years of age and older.
The generics of Twyneo are possible to be released after 12 July, 2038.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination (NC) | Jul 26, 2024 |
Drugs and Companies using BENZOYL PEROXIDE; TRETINOIN ingredient
Market Authorisation Date: 26 July, 2021
Treatment: Topical treatment of acne vulgaris in adults and pediatric patients 9 years of age and older
Dosage: CREAM;TOPICAL
TWYNEO family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic